What is Leerink Partnrs’ Estimate for JAZZ FY2024 Earnings?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for Jazz Pharmaceuticals in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the specialty pharmaceutical company will earn $15.68 per share for the year, down from their prior forecast of $15.88. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.03 per share. Leerink Partnrs also issued estimates for Jazz Pharmaceuticals’ FY2025 earnings at $18.00 EPS and FY2026 earnings at $19.88 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion.

Several other analysts also recently weighed in on the company. Morgan Stanley decreased their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Robert W. Baird dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Needham & Company LLC reiterated a “buy” rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, September 10th. Finally, Wells Fargo & Company decreased their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.14.

Jazz Pharmaceuticals Stock Up 0.4 %

JAZZ stock opened at $115.04 on Friday. The stock has a market capitalization of $7.25 billion, a price-to-earnings ratio of 23.72, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. The company has a 50-day moving average of $110.88 and a two-hundred day moving average of $109.79. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $137.38. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Kovack Advisors Inc. grew its stake in Jazz Pharmaceuticals by 88.8% during the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock worth $6,816,000 after buying an additional 26,628 shares during the last quarter. John G Ullman & Associates Inc. bought a new stake in Jazz Pharmaceuticals during the 1st quarter worth approximately $3,631,000. Swedbank AB acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $106,936,000. Vanguard Group Inc. raised its position in Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after purchasing an additional 84,941 shares during the last quarter. Finally, LSV Asset Management boosted its stake in Jazz Pharmaceuticals by 1.6% in the first quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock worth $286,703,000 after purchasing an additional 37,631 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.